Floatz logo

Cediranib

Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements

Fred Hutchinson Cancer CenterSmall moleculePhase 1Dormant
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

25 Active assets in the Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Mayo Clinic
Phase 2B
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Yazeed Sawalha
Phase 2B
Ibrutinib
National Cancer Institute (NCI)
Phase 2B
DEXAMETHASONE
National Cancer Institute (NCI)
Phase 2B
Epirubicin
Mayo Clinic
Phase 2CCC

View all 31 →

Same molecule, other indications

Cediranib is also rated in:

gliosarcomaDormant
BBB
Indicative ·
76 / 100
View asset →
Recurrent NeuroblastomaDormant
BBB
Indicative ·
73 / 100
View asset →
Recurrent Colon CancerDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →